Content uploaded by Michael Schunck
Author content
All content in this area was uploaded by Michael Schunck on Mar 27, 2023
Content may be subject to copyright.
Orally administered collagen hydrolysate halts the progression of osteoarthritis in STR/ort mice
... Collagen hydrolysate (CH) possesses cartilage healing properties and helps in the Tanbir Ahmad tanbirvet05@rediffmail.com 1 synthesis of bone matrix due to readily available bioactive peptides and amino acids leading to beneficial effects on osteoarthritis, joint disorders and bone. Oral intake of CH retards the development and progression of cartilage damage [4,5]. When ingested, CH is absorbed through gastrointestinal mucosa and gets accumulated in hyaline cartilage [6]. ...
Purpose
This study was conducted to characterize the extract collagen hydrolysate (CH) from low value buffalo skin using enzymes bromelain (B) and papain (P), including their bioactivities.
Methods
Optimum levels of the two enzymes were determined by Sodium dodecyl sulphate-Polyacrylamide gel electrophoresis (SDS-PAGE) and degree of hydrolysis. Levels (30 and 50 units of B/g of skin and 20 and 30 units of P/g of skin) showing maximum degradation of collagen proteins were used to extract CH and the recovered CH were correspondingly referred as B20, B50, P20 and P30, respectively.
Results
The yield of CH from skin for P20, P30, B30 and B50 was 27.38, 26.32, 20.71 and 16.19%, respectively. SDS-PAGE image of the different CH samples showed complete degradation of α- and β- chains of the collagen protein chains revealing only smear bands. 2, 2-Diphenyl-1-picrylhydrazyl (DPPH) scavenging ability was highest (94.51%) for B50 sample followed by 90.59% for P30 at the concentration of 10 mg/ml. Amide I peaks of various CHs as revealed by fourier-transform infrared spectroscopy (FTIR) showed greater disruption in the triple helical structure of collagen chains in P30 and B50 than P20 and B30 samples. Antiarthritic study revealed that B30 and B50 samples had 71.07 and 99.47% inhibition, respectively at the concentration of 50 µg/ml.
Conclusion
Thus, it could be concluded that 30 and 50 units of papain and bromelain per gram of skin, respectively, could be used to extract CH from buffalo skin and better utilize this high protein byproduct into high value food supplement.
... Previous analysis of radiolabeled collagen hydrolysate determined that the orally administered substance was absorbed from the intestine and accumulated preferentially on the cartilage tissue [11]. A randomized placebo control study on animal osteoarthritis (OA) model demonstrated that the oral ingestion of collagen hydrolysate over a Three-month period led to a significant decrease in cartilage tissue degeneration in the knee joints when compared with non-treated subjects [12]. ...
... CH induces the novel synthesis of type 2 collagen and proteoglycans in the extracellular matrix in a dose-dependent manner 10 , is readily absorbed across the gastrointestinal mucosa in murine models and distributes to hyaline cartilage, where it accumulates 11 . In the STR/ort mouse model of spontaneous OA, oral administration of CH reduced both the development and progression of cartilage damage 12,13 . A range of clinical reports and observations suggest that CH may benefit symptoms of OA, with one randomized clinical trial producing mixed results 14 . ...
To determine whether either of two magnetic resonance imaging approaches - delayed gadolinium enhanced magnetic resonance imaging of cartilage (dGEMRIC), or T2 mapping - can detect short-term changes in knee hyaline cartilage among individuals taking a formulation of collagen hydrolysate.
Single center, prospective, randomized, placebo-controlled, double-blind, pilot trial of collagen hydrolysate for mild knee osteoarthritis (OA). Participants were allowed to continue the prior analgesic use. The primary outcome was change in dGEMRIC T1 relaxation time in the cartilage regions of interest at the 24-week timepoint. Secondary endpoints included the change in dGEMRIC T1 relaxation time between baseline and 48 weeks, the change in T2 relaxation time at 0, 24 and 48 weeks, the symptom and functional measures obtained at each of the visits, and overall analgesic use.
Among a sample of 30 randomized subjects the dGEMRIC score increased in the medial and lateral tibial regions of interest (median increase of 29 and 41 ms respectively) in participants assigned to collagen hydrolysate but decreased (median decline 37 and 36 ms respectively) in the placebo arm with the changes between the two groups at 24 weeks reaching significance. No other significant changes between the two groups were seen in the other four regions, or in any of the T2 values or in the clinical outcomes.
These preliminary results suggest that the dGEMRIC technique may be able to detect change in proteoglycan content in knee cartilage among individuals taking collagen hydrolysate after 24 weeks.
Objective
Osteoarthritis (OA) is the most common joint disorder in humans and dogs. Due to its chronic progressive nature, the predominant clinical signs after a certain point are pain and immobility. The similar pathogenesis allows conclusions to be drawn from canine to human OA. Current treatments are limited and often attempt to treat OA symptoms rather than improve joint structure and function. Collagen hydrolysates as oral supplements are a promising therapeutic option to achieve this advanced therapeutic aim in both species. The effects of oral supplementation were therefore investigated in canine OA patients.
Method
In a systematic, placebo-controlled, double-blind interventional study in 31 dogs with naturally occurring OA, the efficacy of oral supplementation of specific bioactive collagen peptides (BCP) was tested in comparison to the approved combination of the active substances omega-3 fatty acids and vitamin E. The dogs were examined on a horizontal treadmill with 4 integrated piezoelectric force plates at the beginning and end of a twelve-week test period. At both points, the owners completed a specific questionnaire containing the validated Canine Brief Pain Inventory (CBPI) and the dogs were fitted with accelerometers to record total daily activity data.
Results
Only the oral supplementation of BCP resulted in a significant improvement of several kinetic parameters measured using a force-plate fitted treadmill, and the quality of life assessed by CBPI, while accelerometry was unaffected by the intervention.
Conclusion
The results of this three-month BCP supplementation study using objective measurement parameters in dogs with naturally occurring OA demonstrate an efficacy, suggesting the therapeutic use of BCP in canine OA patients and demonstrating the relevance of this collagen hydrolysate formulation for the treatment of OA in human patients as well.
Требования украинского и европейского законодательств к разработке растительных препаратов
В статье приведен обзор требований основных нормативных документов к фармацевти-
ческой разработке, исследованиям и регистрации растительных препаратов (РП) и лекар-
ственных средств растительного происхождения (ЛСРП) в Украине и Европейском союзе.
Имплементация требований руководств, разработанных Европейским агентством по лекар-
ственным средствам, в отношении разработки и исследований РП и ЛСРП в отечественное
законодательство является актуальным вопросом современной фармацевтической науки и
практики. Такая имплементация создаст структурированный алгоритм проведения исследо-
ваний при разработке лекарственных форм из РП и ЛСРП.
Ключевые слова: растительные препараты, лекарственные средства растительного проис- хождения, фармацевтическая разработка, Европейский союз
ResearchGate has not been able to resolve any references for this publication.